Updates are available Correction dated 2023-03-30
Click to view Correction: https://doi.org/10.1007/s00216-023-04662-2
-
Authors
Alhasan, Moumen M.
Habazin, Siniša
Kahhaleh, Fariz G.
Lauc, Gordan
Conrad, Melanie L.
Novokmet, Mislav
-
Funding
Funding for this research was provided by:
European Structural and Investment Funds (KK.01.1.1.01.0010)
European Structural and Investment Funds (KK.01.2.2.03.0006)
German Research Foundation (CO 1058/3-2)
- License Information
-
More Information
Article History
Received: 30 December 2022
Revised: 14 February 2023
Accepted: 17 February 2023
First Online: 14 March 2023
Change Date: 30 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00216-023-04662-2
Declarations
:
: All animal experiments were approved by the local authorities (Landesamt für Gesundheit und Soziales; LAGeSo) and were performed in accordance with the German and international guidelines.
: BALB/c mice were obtained from Janvier Labs (53940 Le Genest-Saint-Isle, France).
: The authors declare that the standardized institutional and international procedures for the care and use of laboratory animals compliant with the highest ethical standards were followed in this study.
: Gordan Lauc is the founder and CEO of Genos Ltd., a company specializing in high-throughput glycomics and glycoproteomics. Siniša Habazin and Mislav Novokmet are employees of Genos Ltd. The other authors declare no competing interests.
